Pr DE SEZE Jérôme

PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.

Demuth S, Faddeenkov I, Paris J, Rousseau O, Baciotti B, Payet M, Casey R, Vukusic S, Doyle S, Jarre G, Vince N, Limou S, De Sèze J, Kerbrat A, Laplaud D, Edan G, Gourraud PA,

JAMIA Open. 2026 06;9(3):ooag039

Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

Gavoille A, Kerbrat A, Edan G, Le Page E, Rollot F, Casey R, Mathey G, Stankoff B, Ciron J, De Seze J, Ruet A, Labauge PM, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, David T, Magy L, Camdessanche JP, Moulin S, Doghri I, Sarov M, Dos Santos A, Pottier C, Manchon E, Aboab J, Tchikviladze M, Dahan C, Durozard P, Scherer-Gagou C, Leclancher A, Laplaud DA, Vukusic S, Michel L,

Neurology. 2026 05 26;106(10):e214943

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Roos I, Sharmin S, Horakova D, Kubala Havrdova E, Libertinova J, Vachova M, Alroughani R, Boz C, Rous Z, Buzzard K, Skibina O, Peterka M, Hradilek P, Mares M, Coles A, Brown JWL, Eichau Madueño S, Foschi M, Prevost J, Terzi M, Prat A, Girard M, Meca-Lallana JE, John N, Blanco Y, van der Walt A, Butzkueven H, Recmanova E, Laureys G, Ampapa R, Macdonell R, Pavelek Z, Khoury SJ, D'Amico E, Gerlach O, Van Pesch V, Maimone D, Romero-Ferrando B, McCombe PA, Mrabet S, Willekens B, Cárdenas-Robledo S, Ramo-Tello C, Stourac P, Houskova J, Shaygannejad V, Hodgkinson S, Cartechini E, Kermode AG, Fabis-Pedrini M, Carroll WM, Slee M, Sánchez-Menoyo JL, Al-Asmi A, Mathey G, Giannesini C, Michel L, Ciron J, De Sèze J, Ruet A, Kwiatkowski A, Zephir H, Papeix C, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Camdessanché JP, Doghri I, Tchikviladze M, Sellebjerg F, Romme Christensen J, Jensen HB, Illes Z, Bramow S, Rasmussen PV, Stilund ML, Schäfer J, Kant M, Weglewski A, Vukusic S, Magyari M, Laplaud DA, Kalincik T,

J Neurol Neurosurg Psychiatry. 2026 05 20;:

External validation and improvement of an algorithm that identifies multiple sclerosis relapses in the French national healthcare claims database.

Carcaillon-Bentata L, Abouelfath A, Lignot-Maleyran S, Lassalle R, Jové J, Blin P, Berger E, Bourre B, Camdessanche JP, Casez O, Ciron J, David T, De Seze J, Defer G, Doghri I, Santos AD, Hankiewicz K, Heinzlef O, Labauge P, Page EL, Lebrun-Frenay C, Leclancher A, Louapre C, Manchon E, Mathey G, Montcuquet A, Papeix C, Pelletier J, Pottier C, Ruet A, Sarov-Riviere M, Vukusic S, Magy L, Moulin M, Brochet B, Casey R, Leray E,

Mult Scler Relat Disord. 2026 04 24;111:107209

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Roos I, Sharmin S, Ozakbas S, Alroughani R, Eichau S, Grand'Maison F, Boz C, Lechner-Scott J, Buzzard K, Prat A, Khoury SJ, Grammond P, van der Walt A, Blanco Y, Foschi M, Soysal A, Barnett M, Prevost J, Terzi M, Gerlach O, Macdonell R, Sa MJ, Spitaleri D, Laureys G, van Pesch V, John N, Cartechini E, Gouider R, Maimone D, Ramo-Tello C, Hodgkinson S, Slee M, McCombe P, Garber J, Sanchez-Menoyo JL, Al-Asmi A, Kermode AG, Lapointe E, Shaygannejad V, Van Wijmeersch B, Willekens B, Castillo-Triviño T, Taylor B, Mathey G, Le Page E, De Seze J, Ruet A, Clavelou P, Berger E, Zephir H, Kwiatkowski A, Pelletier J, Moreau T, Labauge P, Ciron J, Lebrun-Frenay C, Papeix C, Defer G, Laplaud DA, Thouvenot E, Stankoff B, Maillart E, Al-Khedr A, Bourre B, Casez O, Dos Santos A, Camdessanche JP, Hankiewicz K, Wahab A, Cabre P, Heinzlef O, Pottier C, Moulin S, Magy L, Labeyrie C, Doghri I, Vukusic S, Kalincik T,

CNS Drugs. 2026 04 4;:

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges.

Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J

Neurol Ther. 2026 03 19;:

A multidimensional analysis of neuropsychiatric lupus: clinical, biological and imaging insights from systematic evidence.

Matmat K, Jamann H, Maazouzi A, Bigaut K, Maitre M, De Seze J, Mensah-Nyagan AG, Jeltsch-David H

Front Immunol. 2026 03 16;17:1768131

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Bennett JL, Bhattacharyya S, Zabeti A, Levy M, de Sèze J, Taney MJ, Parks B, Allen K, Akpoji U, Pittock SJ

Mult Scler. 2026 03 4;:13524585261425076

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Rommer PS, Jiang W, Nolte JP, Mikami T, De Seze J, Sánchez P, Harel A, Alkabie S, Kaneko K, Bilodeau PA, Misu T, Kremer L, Bigaut K, Leypoldt F, Aktas O, Ringelstein M, Siffrin V, Zhang LJ, Cong H, Lowe M, Barreras P, Chen H, Piquet AL, Sotirchos ES, Kammeyer R, Zook J, Bennett JL, Berger T, Fujihara K, Levy M, Shi FD, Paul F

Neurol Neuroimmunol Neuroinflamm. 2026 03;13(2):e200548

Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.

Rollot F, Casey R, Kerbrat A, Edan G, Le Page E, Vukusic S, Mathey G, Maillart E, De Sèze J, Ciron J, Ruet A, Labauge P, Papeix C, Zephir H, Lebrun-Frenay C, Defer G, Moreau T, Berger E, Clavelou P, Heinzlef O, Thouvenot E, Pelletier J, Casez O, Bourre B, Wahab A, Moulin S, Kwiatkowski A, David T, Magy L, Camdessanché JP, Doghri I, Dos Santos A, Hankiewicz K, Sarov Riviere M, Manchon E, Pottier C, Tchikviladze M, Scherer Gagou C, Dahan C, Durozard P, Laplaud DA, Michel L

Brain. 2026 02 14;:

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.

Hauser SL, Freedman MS, Nakahara J, Paling D, de Seze J, Li J, Abeyewickreme A, Wu M, Sullivan R, Pardo G, Montalban X, Wiendl H

Mult Scler Relat Disord. 2025 11 25;105:106886

Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica.

Salih H, Samadzadeh S, Bereuter C, Motamedi S, Chien C, Villoslada P, Stiebel-Kalish H, Asgari N, Mao-Draayer Y, Ringelstein M, Havla J, Peixoto MAL, Kim HJ, Palace J, Leite MI, Sharma SM, Ashtari F, Kafieh R, Pandit L, Aktas O, Albrecht P, Leocani L, Lotan I, Siritho S, de Seze J, Marignier R, Tilikete CF, Bichuetti DB, Tavares IM, Altintas A, Jacob A, Huda S, de Castillo IS, Cook LJ, Yeaman MR, Petzold A, Brandt AU, Paul F, Oertel FC, Zimmermann HG,

Ann Clin Transl Neurol. 2025 11 17;:

Privacy-by-Design Approach to Generate Two Virtual Clinical Trials for Multiple Sclerosis and Release Them as Open Datasets: Evaluation Study.

Demuth S, Rousseau O, Faddeenkov I, Paris J, De Sèze J, Baciotti B, Payet M, Guillaudeux M, Barreteau AF, Laplaud D, Edan G, Gourraud PA

J Med Internet Res. 2025 10 1;27:e71297

Pembrolizumab-Induced High Inflammatory Panmyelitis: Contribution of Neurochemical Markers Predicting Severity of Central Nervous Affection.

Hagenkötter B, De Sèze J, Hammami F, Klopfenstein T, Zayet S

Oncol Ther. 2025 09 5;:

Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.

Gavoille A, Nourredine M, Rollot F, Casey R, Mathey G, Kerbrat A, Ciron J, De Sèze J, Stankoff B, Maillart E, Ruet A, Labauge P, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanché JP, Doghri I, Sarov M, Hankiewicz K, Pottier C, Dos Santos A, Manchon E, Tchikviladze M, Rabilloud M, Subtil F, Vukusic S

J Neurol Neurosurg Psychiatry. 2025 09 4;:

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.

Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG, Patti F, Kleiter I, Palace J, De Seze J, Evans R, Blondeau K, Klingelschmitt G, Vodopivec I, Rahim M, Yamamura T

Neurol Neuroimmunol Neuroinflamm. 2025 09;12(5):e200450

Advancing medical training with augmented reality and haptic feedback simulator: outcomes of a randomized controlled trial on lumbar puncture.

Felten R, Bigaut K, Wirth T, Kremer L, Gauer L, Arnold C, Ollivier I, Godet J, Scherlinger M, Dubois M, Sebbag E, De Sèze J, Gottenberg JE

BMC Med Educ. 2025 08 30;25(1):1231

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Gavoille A, Leray E, Marignier R, Rollot F, Casey R, Mathey G, Michel L, De Seze J, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Laplaud DA, Papeix C, Defer G, Moreau T, Berger E, Dubessy AL, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, Magy L, Camdessanche JP, Doghri I, Moulin S, Labeyrie C, Hankiewicz K, Dos Santos A, Pottier C, Manchon E, Tchikviladze M, Lebrun-Frenay C, Vukusic S,

Neurology. 2025 08 26;105(4):e213907

Evolution of high-efficacy treatment strategy for relapsing-remitting multiple sclerosis: A real-life observational study.

Didierjean J, Kremer L, Lanotte L, Courtois S, Carré G, Collongues N, De Seze J, Bigaut K

Mult Scler Relat Disord. 2025 08 17;104:106690

Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.

Robin C, Rollot F, Lefort M, Casey R, Vukusic S, Mathey G, Ciron J, De Seze J, Stankoff B, Maillart E, Ruet A, Labauge PM, Kwiatkowski A, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanche JP, Doghri I, Sarov M, Hankiewicz K, Pottier C, Dos Santos A, Manchon E, Tchikviladze M, Nifle C, Kerbrat A, Edan G, Le Page E, Michel L,

Neurology. 2025 08 12;105(3):e213744

Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis.

Garcia A, Rodriguez S, Dugast E, Lebrun-Frenay C, Thouvenot E, de Sèze J, Le Page E, Vukusic S, Doghri I, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Le Frère F, Nicot AB, Wiertlewski S, Gourraud PA, Michel L, Berthelot L, Laplaud DA

Ann Clin Transl Neurol. 2025 08 8;:

Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.

Gavoille A, Rollot F, Casey R, Mathey G, Le Page E, Ciron J, De Sèze J, Ruet A, Maillart E, Labauge P, Zephir H, Kwiatkowski A, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Dubessy AL, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Wahab A, Magy L, Moulin S, Camdessanché JP, Doghri I, Sarov-Riviere M, Hankiewicz K, Pottier C, Dos Santos A, Nifle C, Subtil F, Vukusic S,

JAMA Neurol. 2025 08 4;:

Criteria for the use of plasmapheresesis in optic neuritis: A practice review from French expert centers.

Gaulier A, Touitou V, Rougier MB, Robert MP, Merle H, Aubart M, Cabre P, Cochard C, Stolowy N, De Seze J, Gueguen A, Aboab J, Zephir H, Ungureanu A, Caignard A, Scherer C, Gobert M, Saheb S, Fage N, Ducloyer JB, Rivet A, Beltran S, Guennoc AM, Audoin B, Laville MA, Branger P, Khanna R, Roth C, Bensa C, Bursztyn J, Biotti D, Laplaud D, Brochet B, Wiertlewski S, Froment C, Lebranchu P

Rev Neurol (Paris). 2025 07 15;:

Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.

Hauser SL, Cohen JA, de Sèze J, Meuth SG, Giacomini PS, Nakahara J, Oreja-Guevara C, Robertson D, Wray S, Bhatt A, Hu X, Xi J, Piccolo R, Jehl V, Sullivan R, Boer I, Wiendl H, Kappos L

Neurol Ther. 2025 07 13;:

Beyond the switch to the biosimilar of natalizumab: What is the impact of changing the JCV test?

Vukusic S, Hubben F, Gavoille A, Malek Y, Casez O, Kremer L, Palpacuer T, Marignier R, Durand-Dubief F, Androdias-Condemine G, Pique J, Maillart E, Vermersch P, de Seze J

Mult Scler. 2025 06;31(7):877-881

Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort.

Samadzadeh S, Oertel FC, Salih H, Lin TY, Motamedi S, Chien C, Cook LJ, Lana-Peixoto MA, Fontenelle MA, Kim HJ, Hyun JW, Jung SK, Palace J, Roca-Fernandez A, Leite MI, Sharma SM, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, Dcunha A, Aktas O, Ringelstein M, Albrecht P, May EF, Tongco C, Leocani L, Pisa M, Radaelli M, Sánchez-Dalmau B, Martinez-Lapiscina EH, Stiebel-Kalish H, Hellmann MA, Lotan I, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Tilikete CF, Cobo-Calvo A, Bichuetti D, Tavares IM, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, Villoslada P, de Castillo IS, Green A, Petzold A, Yeaman MR, Smith TJ, Brandt AU, Zimmermann HG, Paul F, Asgari N,

Eur J Neurol. 2025 06;32(6):e70214

An update on the evaluation of treatment switching criteria in multiple sclerosis.

Bigaut K, Didierjean J, de Seze J

Expert Rev Neurother. 2025 05 13;:

Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study.

Cohen M, Rollot F, Debouverie M, Zephir H, Vukusic S, De Seze J, Labauge P, Landes-Chateau C, Mondot L, Levraut M, Ruet A, Berger E, Laplaud D, Ciron J, Bourre B, Le Page E, Papeix C, Thouvenot E, Al Khedr A, Stankoff B, Pelletier J, Maillart E, Casez O, Moreau T, Defer G, Clavelou P, Cabre P, Moulin S, Neau JP, Zedet M, Hankiewicz K, Doghri I, Nasr HB, Pottier C, Magy L, Boulos DD, Heinzlef O, Camdessanche JP, Coustans M, Nifle C, Brassat D, Casey R, Lebrun-Frenay C,

Eur J Neurol. 2025 05;32(5):e16583

Brain health - time matters: multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and related conditions. 2024 report.

Butzkueven H, Arkelsten S, Comi G, Costello K, Devlin M, Drulovic J, Gray E, Haartsen J, Helme A, Hlavácová J, Kasilingam E, Liu Y, Mathew T, Reyes S, de Sèze J, Williams MJ, Giovannoni G

Mult Scler Relat Disord. 2025 04 19;101:106456

Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis in France: The TITAN Study.

Vermersch P, Kwiatkowski A, de Sèze J, Créange A, Texier N, Fantoni-Quinton S, Gros M, Ruiz M, Lebrun-Frenay C,

Neurol Ther. 2025 04 10;:

Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.

Hong J, Gaubert M, Lefort M, Ferré JC, Le Page E, Michel L, Labauge P, Pelletier J, de Seze J, Durand-Dubief F, Cotton F, Edan G, Bannier E, Combès B, Kerbrat A

J Neurol. 2025 04 5;272(4):316

Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette Study.

Vermersch P, Moisset X, Roux B, Lecomte A, Luciani L, Paret M, de Sèze J

Neurol Ther. 2025 03 23;:

European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?

de Seze J, Zecca C, Castelnovo G, Ayrignac X, Vermersch P, Gobbi C, Mallucci G, Carra-Dallière C, Labauge P, Bigaut K, Kremer L, Collongues N, Lanotte L, Thouvenot E, Ernon C, Dive D

Mult Scler J Exp Transl Clin. 2025 03 17;11(1):20552173251321810

High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial.

Thouvenot E, Laplaud D, Lebrun-Frenay C, Derache N, Le Page E, Maillart E, Froment-Tilikete C, Castelnovo G, Casez O, Coustans M, Guennoc AM, Heinzlef O, Magy L, Nifle C, Ayrignac X, Fromont A, Gaillard N, Caucheteux N, Patry I, De Sèze J, Deschamps R, Clavelou P, Biotti D, Edan G, Camu W, Agherbi H, Renard D, Demattei C, Fabbro-Peray P, Mura T, Rival M,

JAMA. 2025 03 10;:

Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis.

Mainguy M, Casey R, Vukusic S, Lebrun-Frenay C, Berger E, Kerbrat A, Al Khedr A, Bourre B, Ciron J, Clavelou P, De Seze J, Defer G, Doghri I, Dos Santos A, Hankiewicz K, Labauge PM, Le Page E, Magy L, Maillart E, Manchon E, Michel L, Moreau T, Moulin S, Pelletier J, Pottier C, Ruet A, Sarov M, Stankoff B, Thouvenot E, Wahab A, Zephir H, Leray E, Laplaud DA

Neurol Neuroimmunol Neuroinflamm. 2025 03;12(2):e200371

LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France.

de Sèze J, Labauge P, Liblau R, Martinez M, Moreau T, Suchet L, Vermersch P, Vukusic S, Mathey G, Michel L, Ciron J, Ruet A, Maillart E, Zephir H, Papeix C, Defer G, Cohen M, Laplaud DA, Berger E, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Giannesini C, Casez O, Bourre B, Wahab A, Magy L, Camdessanché JP, Doghri I, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Dobay P, Li H, Levin S, Gros M, Ruiz M, Rollot F

Adv Ther. 2025 02 19;:

Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint.

Demuth S, De Sèze J, Edan G, Ziemssen T, Simon F, Gourraud PA

JMIR Med Inform. 2025 01 28;13:e53542

Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.

Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H, ,,,,

J Neurol Neurosurg Psychiatry. 2024 12 6;:

Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.

Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Michel L, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E

Mult Scler. 2024 12 1;:13524585241289276

Association between education level and disability progression in patients with multiple sclerosis in France.

Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Le Page E, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E

Mult Scler. 2024 11 30;:13524585241289274

Assessment of the concomitant action of XBD173 and interferon β in a mouse model of multiple sclerosis using infrared marker bands.

Sirinukunwattana K, Klein C, Clarke PFA, Marcou G, Meyer L, Collongues N, de Sèze J, Hellwig P, Patte-Mensah C, El Khoury Y, Mensah-Nyagan AG

Spectrochim Acta A Mol Biomol Spectrosc. 2024 11 3;327:125390

Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.

Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Sèze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frénay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zéphir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanché JP, Doghri I, Wahab A, Tchikviladzé M, Labeyrie C, Hankiewicz K, Le Page E, Michel L,

Neurology. 2024 10 22;103(8):e209886

Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants.

Chalouni M, Loubet P, Lhomme E, Ninove L, Barrou B, Blay JY, Hourmant M, de Seze J, Laville M, Laviolle B, Lelièvre JD, Morel J, Quoc SN, Spano JP, Terrier B, Thiebaut A, Viallard JF, Vrtovsnik F, Circosta S, Barquin A, Gharib M, Tartour E, Parfait B, Thiébaut R, Meyer L, de Lamballerie X, Launay O, Wittkop L,

BMC Infect Dis. 2024 09 27;24(1):1049

Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.

Oertel FC, Zimmermann HG, Motamedi S, Bereuter C, Manthey LM, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Aktas O, Albrecht P, Ringelstein M, Martinez-Lapiscina EH, Sanchez Dalmau BF, Villoslada P, Asgari N, Marignier R, Cobo-Calvo A, Leocani L, Pisa M, Radaelli M, Palace J, Roca-Fernandez A, Leite MIS, Sharma S, De Seze J, Senger T, Yeaman MR, Smith TJ, Cook LJ, Brandt AU, Paul F,

Neurol Neuroimmunol Neuroinflamm. 2024 09;11(5):e200273

Teriflunomide, cognition and MRI: A longitudinal study.

Pfaff L, Mondino M, Loeb Q, Noblet V, Berthe C, Kremer L, Bigaut K, Collongues N, De Seze J

Mult Scler Relat Disord. 2024 07 31;90:105793

Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.

Gavoille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K, Mathey G, Michel L, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Manchon E, Lapergue B, Wiertlewski S, De Sèze J, Vukusic S, Laplaud DA,

JAMA Neurol. 2024 07 1;:

Scoping review of clinical decision support systems for multiple sclerosis management: Leveraging information technology and massive health data.

Demuth S, Ed-Driouch C, Dumas C, Laplaud D, Edan G, Vince N, De Sèze J, Gourraud PA

Eur J Neurol. 2024 06 11;:e16363

Clinical applications of deep learning in neuroinflammatory diseases: A scoping review.

Demuth S, Paris J, Faddeenkov I, De Sèze J, Gourraud PA

Rev Neurol (Paris). 2024 05 20;:

Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.

Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA

Neurology. 2024 05 14;102(9):e209357

Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.

Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F,

J Neurol Neurosurg Psychiatry. 2024 05 10;:

Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis.

de Seze J, Dive D, Ayrignac X, Castelnovo G, Payet M, Rayah A, Gobbi C, Vermersch P, Zecca C

Neurol Ther. 2024 04 8;:

The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.

Makhani N, Lebrun-Frenay C, Siva A, Shabanova V, Wassmer E, Santoro JD, Narula S, Brenton JN, Mar S, Durand-Dubief F, Zephir H, Mathey G, Rojas JI, de Seze J, Tenembaum S, Stone RT, Casez O, Carra-Dallière C, Neuteboom RF, Ahsan N, Arroyo HA, Cabre P, Gombolay G, Inglese M, Louapre C, Margoni M, Palavra F, Pohl D, Reich DS, Ruet A, Thouvenot E, Timby N, Tintore M, Uygunoglu U, Vargas W, Venkateswaran S, Verhelst H, Wickstrom R, Azevedo CJ, Kantarci O, Shapiro ED, Okuda DT, Pelletier D,

J Neurol. 2024 04 2;:

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.

Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A,

JAMA Neurol. 2024 03 25;:

Holistic, Long-Term Management of People with Relapsing Multiple Sclerosis with Cladribine Tablets: Expert Opinion from France.

Ciron J, Bourre B, Castelnovo G, Guennoc AM, De Sèze J, Ben-Amor AF, Savarin C, Vermersch P

Neurol Ther. 2024 03 15;:

Efficacy of dalfampridine in neuromyelitis optica spectrum disorder: A pilot study.

de Seze J, Clerc C, Béreau M, Bourre B, Zephir H, Collongues N, Kremer L, Vermersch P, Bigaut K

Mult Scler J Exp Transl Clin. 2024 02 29;10(1):20552173241233952

Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.

Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA,

JAMA Neurol. 2024 02 12;:

Real-life study to assess effectiveness and safety of eculizumab in patients with neuromyelitis optica spectrum disorders in France: protocol for ECUP4, an observational study.

Marignier R, Laplaud D, Zéphir H, Papeix C, Leray E, Amri E, Piotaix M, de Sèze J

Front Neurol. 2024 01 22;14:1303874

COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.

Jeantin L, Januel E, Labauge P, Maillart E, de Seze J, Zéphir H, Pelletier J, Kerschen P, Biotti D, Heinzlef O, Guilloton L, Bensa C, Théaudin M, Vukusic S, Casez O, Maurousset A, Laplaud D, Berger E, Lebrun-Frenay C, Bourre B, Branger P, Stankoff B, Clavelou P, Thouvenot E, Manchon E, Moreau T, Sellal F, Zedet M, Papeix C, Louapre C

Mult Scler. 2024 01 21;:13524585231218149

Comparison of Two Methods for Estimating MS-Related Mortality: The Excess Mortality vs. the Cause-Specific Frameworks.

Rollot F, Uhry Z, Dantony E, Vukusic S, Debouverie M, Le Page E, Ciron J, Ruet A, De Seze J, Zephir H, Labauge PM, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Clavelou P, Pelletier J, Thouvenot E, Heinzlef O, Camdessanche JP, Fauvernier M, Remontet L, Leray E

Neurology. 2023 10 12;:

Strokecopilot: a literature-based clinical decision support system for acute ischemic stroke treatment.

Demuth S, Müller J, Quenardelle V, Lauer V, Gheoca R, Trzeciak M, Pierre-Paul I, De Sèze J, Gourraud PA, Wolff V

J Neurol. 2023 09 5;:

Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial.

Lebrun-Frénay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, Vermersch P, Papeix C, Thouvenot E, Labauge P, Durand-Dubief F, Efendi H, Le Page E, Terzi M, Derache N, Bourre B, Hoepner R, Karabudak R, De Seze J, Ciron J, Clavelou P, Wiertlewski S, Turan OF, Yucear N, Cohen M, Azevedo C, Kantarci OH, Okuda DT, Pelletier D,

JAMA Neurol. 2023 08 21;:

Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.

Moreau A, Kolitsi I, Kremer L, Fleury M, Lanotte L, Sellal F, Gaultier C, Ahle G, Courtois S, Fickl A, Mostoufizadeh S, Dentel C, Collongues N, de Seze J, Bigaut K

Mult Scler Relat Disord. 2023 08 13;79:104942

The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers.

Brocard G, Casey R, Dufay N, Marignier R, Michel L, Hisbergues M, Ayrignac X, Lehmann S, Thouvenot E, Gallot G, Collongues N, Herpe YE, Lebrun-Frenay C, Cotton F, De Sèze J, Guillemin F, Moreau T, Pelletier J, Stankoff B, Vukusic S, Zephir H, Laplaud D,

Mult Scler Relat Disord. 2023 07 7;77:104872

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.

Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A

Neurol Neuroimmunol Neuroinflamm. 2023 07;10(4):

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis.

Clavelou P, Castelnovo G, Pourcher V, De Sèze J, Vermersch P, Ben-Amor AF, Savarin C, Defer G

Neurol Ther. 2023 06 29;:

Impact of COVID-19 vaccination or infection on disease activity in a radiologically isolated syndrome cohort: The VaxiRIS study.

Cohen M, Thomel-Rocchi O, Siva A, Okuda DT, Karabudak R, Efendi H, Terzi M, Carra-Dalliere C, Durand-Dubief F, Thouvenot E, Ciron J, Zephir H, Bourre B, Casez O, De Seze J, Moreau T, Neau JP, Pelletier D, Kantarci O, Tutuncu M, Derache N, Bensa C, Louapre C, Benoit J, Landes-Chateau C, Lebrun-Frenay C

Mult Scler. 2023 06 15;:13524585231179669

Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder.

Demuth S, Collongues N, Audoin B, Ayrignac X, Bourre B, Ciron J, Cohen M, Deschamps R, Durand-Dubief F, Maillart E, Papeix C, Ruet A, Zephir H, Marignier R, De Seze J,

Neurology. 2023 06 8;:

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.

Januel E, Hajage D, Labauge P, Maillart E, De Sèze J, Zephir H, Pelletier J, Guilloton L, Bensa C, Heinzlef O, Casez O, Biotti D, Bourre B, Vukusic S, Maurousset A, Berger E, Laplaud D, Lebrun-Frénay C, Dubessy AL, Branger P, Thouvenot E, Clavelou P, Sellal F, Manchon E, Moreau T, Papeix C, Tubach F, Louapre C

JAMA Netw Open. 2023 06 1;6(6):e2319766

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.

Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D

Neurol Neuroimmunol Neuroinflamm. 2023 05;10(3):

Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review.

Pinto AA, De Seze J, Jacob A, Reddel S, Yudina A, Tan K

Ther Adv Neurol Disord. 2023 03 29;16:17562864231154306

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.

de Sèze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, Zephir H, Zimmer L, Biotti D, Liblau R

Front Immunol. 2023 03 23;14:1004795

Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Pittock SJ, Barnett M, Bennett JL, Berthele A, de Seze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ

Ann Neurol. 2023 03 3;:

The radiologically isolated syndrome: revised diagnostic criteria.

Lebrun-Frénay C, Okuda DT, Siva A, Landes-Chateau C, Azevedo CJ, Mondot L, Carra-Dallière C, Zephir H, Louapre C, Durand-Dubief F, Le Page E, Bensa C, Ruet A, Ciron J, Laplaud DA, Casez O, Mathey G, de Seze J, Zeydan B, Makhani N, Tutuncu M, Levraut M, Cohen M, Thouvenot E, Pelletier D, Kantarci OH,

Brain. 2023 03 2;:

A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study.

Gauer L, Bigaut K, Berger É, Debouverie M, Moreau T, de Sèze J

Rev Neurol (Paris). 2023 02 23;:

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort.

Pelle J, Briant AR, Branger P, Derache N, Arnaud C, Lebrun-Frenay C, Cohen M, Mondot L, De Seze J, Bigaut K, Collongues N, Kremer L, Ricard D, Bompaire F, Ohlmann C, Sallansonnet-Froment M, Ciron J, Biotti D, Pignolet B, Parienti JJ, Defer G

Neurol Ther. 2023 02 10;:

Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.

Wilson S, Calocer F, Rollot F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zephir H, Moreau T, Lebrun-Frénay C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Leray E, Dejardin O, Defer G

Lancet Reg Health Eur. 2023 01;24:100542

Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study.

Levraut M, Laurent-Chabalier S, Ayrignac X, Bigaut K, Rival M, Squalli S, Zéphir H, Alberto T, Pekar JD, Ciron J, Biotti D, Puissant-Lubrano B, Camdessanché JP, Tholance Y, Casez O, Toussaint B, Marion J, Moreau T, Lakomy D, Thomasset A, Maillart E, Sterlin D, Maurousset A, Rocher A, Laplaud DA, Bigot-Corbel E, Bertho PO, Pelletier J, Boucraut J, Labauge P, Vincent T, De Sèze J, Jahn I, Seitz-Polski B, Thouvenot E, Lebrun-Frenay C,

Neurol Neuroimmunol Neuroinflamm. 2023 01;10(1):

The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.

De Sèze J, Suchet L, Mekies C, Manchon E, Labauge P, Guennoc AM, Defer G, Clavelou P, Castelnovo G, Bourre B, Bensa-Koscher C, Al Khedr A, Le Mao J, Villemur L, Bouée S, Luciani L, Vermersch P

Neurol Ther. 2022 12 24;:

Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.

Gavoille A, Rollot F, Casey R, Debouverie M, Le Page E, Ciron J, De Seze J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Maurousset A, Moulin S, Ben NH, Boulos DD, Hankiewicz K, Neau JP, Pottier C, Nifle C, Rabilloud M, Subtil F, Vukusic S,

Neurology. 2022 12 23;:

Reverse Takotsubo cardiomyopathy as a complication of MOG-antibody-associated disease (MOGAD)? A case report.

Bogdan T, El Ghannudi S, Demuth S, Kremer L, De Seze J, Bigaut K

Rev Neurol (Paris). 2022 11;178(9):981-983

Diagnosis and classification of optic neuritis.

Petzold A, Fraser CL, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R, Andris C, Asgari N, Barnett Y, Battistella R, Behbehani R, Berger T, Bikbov MM, Biotti D, Biousse V, Boschi A, Brazdil M, Brezhnev A, Calabresi PA, Cordonnier M, Costello F, Cruz FM, Cunha LP, Daoudi S, Deschamps R, de Seze J, Diem R, Etemadifar M, Flores-Rivera J, Fonseca P, Frederiksen J, Frohman E, Frohman T, Tilikete CF, Fujihara K, Gálvez A, Gouider R, Gracia F, Grigoriadis N, Guajardo JM, Habek M, Hawlina M, Martínez-Lapiscina EH, Hooker J, Hor JY, Howlett W, Huang-Link Y, Idrissova Z, Illes Z, Jancic J, Jindahra P, Karussis D, Kerty E, Kim HJ, Lagrèze W, Leocani L, Levin N, Liskova P, Liu Y, Maiga Y, Marignier R, McGuigan C, Meira D, Merle H, Monteiro MLR, Moodley A, Moura F, Muñoz S, Mustafa S, Nakashima I, Noval S, Oehninger C, Ogun O, Omoti A, Pandit L, Paul F, Rebolleda G, Reddel S, Rejdak K, Rejdak R, Rodriguez-Morales AJ, Rougier MB, Sa MJ, Sanchez-Dalmau B, Saylor D, Shatriah I, Siva A, Stiebel-Kalish H, Szatmary G, Ta L, Tenembaum S, Tran H, Trufanov Y, van Pesch V, Wang AG, Wattjes MP, Willoughby E, Zakaria M, Zvornicanin J, Balcer L, Plant GT

Lancet Neurol. 2022 09 27;:

Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.

Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T, ,

Neurology. 2022 08 17;:

Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.

Lescot L, Lefort M, Leguy S, Le Page E, Vukusic S, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, Leray E, Michel L

Mult Scler Relat Disord. 2022 08 15;68:104122

Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.

Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B

Mult Scler Relat Disord. 2022 07 5;66:104025

COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients.

Leguy S, Lefort M, Lescot L, Michaud A, Vukusic S, Le Page E, Edan G, Kerbrat A, Lebrun-Frenay C, De Sèze J, Laplaud DA, Wiertlewski S, Leray E, Michel L

J Neurol. 2022 06 23;:

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Lefort M, Sharmin S, Andersen JB, Vukusic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Ben Nasr H, Hankiewicz K, Pottier C, Maubeuge N, Dimitri-Boulos D, Nifle C, Laplaud DA, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Eichau S, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Shaygannejad V, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Karabudak R, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Koch-Henriksen N, Sellebjerg F, Soerensen PS, Hilt Christensen CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Butzkueven H, Magyari M, Kalincik T, Leray E

BMC Med Res Methodol. 2022 05 30;22(1):155

A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.

Collongues N, Becker G, Jolivel V, Ayme-Dietrich E, de Seze J, Binamé F, Patte-Mensah C, Monassier L, Mensah-Nyagan AG

Neurol Ther. 2022 05 24;:

Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients.

Einsiedler M, Kremer L, Fleury M, Collongues N, De Sèze J, Bigaut K

J Neurol. 2022 Apr 17;:

Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera.

El Khoury Y, Gebelin M, de Sèze J, Patte-Mensah C, Marcou G, Varnek A, Mensah-Nyagan AG, Hellwig P, Collongues N

Int J Mol Sci. 2022 Mar 3;23(5):

Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.

Rollot F, Couturier J, Casey R, Wiertlewski S, Debouverie M, Pelletier J, De Sèze J, Labauge P, Ruet A, Thouvenot E, Ciron J, Berger E, Gout O, Clavelou P, Stankoff B, Casez O, Bourre B, Zephir H, Moreau T, Lebrun-Frenay C, Maillart E, Edan G, Neau JP, Montcuquet A, Cabre P, Camdessanché JP, Defer G, Nasr HB, Maurousset A, Hankiewicz K, Pottier C, Leray E, Vukusic S, Laplaud DA

Neurotherapeutics. 2022 Feb 25;:

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype.

Brochet B, Clavelou P, Defer G, De Seze J, Louapre C, Magnin E, Ruet A, Thomas-Anterion C, Vermersch P

Brain Sci. 2022 Jan 29;12(2):

Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab.

Demuth S, Bogdan T, Kremer L, Lanotte L, Collongues N, de Seze J, Bigaut K

J Neurol. 2022 Jan 19;:

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.

Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M, Gaultier C, Courtois S, Collongues N, de Seze J

J Neurol. 2022 Jan 4;:

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.

Januel E, De Seze J, Vermersch P, Maillart E, Bourre B, Pique J, Moisset X, Bensa C, Maarouf A, Pelletier J, Vukusic S, Audoin B, Louapre C

Mult Scler. 2021 Dec 21;:13524585211049737

COVID-19 exposure in SARS-CoV-2-seropositive hospital staff members during the first pandemic wave at Strasbourg University Hospital, France.

Velay A, Gallais F, Wendling MJ, Bayer S, Reix N, Schneider A, Glady L, Collongues N, Lessinger JM, Hansmann Y, Kling-Pillitteri L, De Sèze J, Gonzalez M, Schmidt-Mutter C, Meyer N, Fafi-Kremer S

Infect Dis Now. 2021 Nov 11;:

Emotional experience is increased and emotion recognition decreased in multiple sclerosis.

Pfaff L, Gounot D, Chanson JB, de Seze J, Blanc F

Sci Rep. 2021 Nov 8;11(1):21885

Retinal Optical Coherence Tomography in Neuromyelitis Optica.

Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S, Bereuter C, Cook L, Lana Peixoto MA, Fontanelle MA, Kim HJ, Hyun JW, Palace J, Roca-Fernandez A, Leite MI, Sharma S, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Aktas O, Ringelstein M, Albrecht P, May E, Tongco C, Leocani L, Pisa M, Radaelli M, Martinez-Lapiscina EH, Stiebel-Kalish H, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Calvo AC, Bichuetti D, Tavares IM, Asgari N, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, Soto de Castillo I, Petzold A, Green AJ, Yeaman MR, Smith T, Brandt AU, Paul F

Neurol Neuroimmunol Neuroinflamm. 2021 Nov;8(6):

Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders.

Lu A, Zimmermann HG, Specovius S, Motamedi S, Chien C, Bereuter C, Lana-Peixoto MA, Fontenelle MA, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, D'Cunha A, Kim HJ, Hyun JW, Jung SK, Leocani L, Pisa M, Radaelli M, Siritho S, May EF, Tongco C, De Sèze J, Senger T, Palace J, Roca-Fernández A, Leite MI, Sharma SM, Stiebel-Kalish H, Asgari N, Soelberg KK, Martinez-Lapiscina EH, Havla J, Mao-Draayer Y, Rimler Z, Reid A, Marignier R, Cobo-Calvo A, Altintas A, Tanriverdi U, Yildirim R, Aktas O, Ringelstein M, Albrecht P, Tavares IM, Bichuetti DB, Jacob A, Huda S, Soto de Castillo I, Petzold A, Green AJ, Yeaman MR, Smith TJ, Cook L, Paul F, Brandt AU, Oertel FC,

J Neurol Neurosurg Psychiatry. 2021 Oct 28;:

Multiple sclerosis diagnostic criteria: from Poser to the 2017 revised McDonald criteria.

de Seze J, Bigaut K

Presse Med. 2021 Oct 27;:104089

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.

Sharmin S, Lefort M, Andersen JB, Leray E, Horakova D, Havrdova EK, Alroughani R, Izquierdo G, Ozakbas S, Patti F, Onofrj M, Lugaresi A, Terzi M, Grammond P, Grand'Maison F, Yamout B, Prat A, Girard M, Duquette P, Boz C, Trojano M, McCombe P, Slee M, Lechner-Scott J, Turkoglu R, Sola P, Ferraro D, Granella F, Prevost J, Maimone D, Skibina O, Buzzard K, Van der Walt A, Van Wijmeersch B, Csepany T, Spitaleri D, Vucic S, Casey R, Debouverie M, Edan G, Ciron J, Ruet A, De Sèze J, Maillart E, Zephir H, Labauge P, Defer G, Lebrun-Frénay C, Moreau T, Berger E, Clavelou P, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Laplaud D, Koch-Henriksen N, Sellebjerg FT, Soerensen PS, Pfleger CC, Rasmussen PV, Jensen MB, Frederiksen JL, Bramow S, Mathiesen HK, Schreiber KI, Magyari M, Vukusic S, Butzkueven H, Kalincik T,

CNS Drugs. 2021 Sep 18;:

Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.

Bigaut K, Kremer L, Fabacher T, Lanotte L, Fleury MC, Collongues N, de Seze J

Neurol Neuroimmunol Neuroinflamm. 2021 Sep;8(5):

Myelin-oligodendrocyte glycoprotein antibody-associated disease.

Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, Brilot F, Capobianco M, Chitnis T, Ciccarelli O, Deiva K, De Sèze J, Fujihara K, Jacob A, Kim HJ, Kleiter I, Lassmann H, Leite MI, Linington C, Meinl E, Palace J, Paul F, Petzold A, Pittock S, Reindl M, Sato DK, Selmaj K, Siva A, Stankoff B, Tintore M, Traboulsee A, Waters P, Waubant E, Weinshenker B, Derfuss T, Vukusic S, Hemmer B

Lancet Neurol. 2021 Sep;20(9):762-772

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.

Gallais F, Gantner P, Bruel T, Velay A, Planas D, Wendling MJ, Bayer S, Solis M, Laugel E, Reix N, Schneider A, Glady L, Panaget B, Collongues N, Partisani M, Lessinger JM, Fontanet A, Rey D, Hansmann Y, Kling-Pillitteri L, Schwartz O, De Sèze J, Meyer N, Gonzalez M, Schmidt-Mutter C, Fafi-Kremer S

EBioMedicine. 2021 Aug 26;71:103561

MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis.

Tanoh IC, Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Vallée M, Bieuvelet S, Klaeylé L, Argoud AL, Zinaï S, Tourbah A

Mult Scler Relat Disord. 2021 Jul 23;55:103164

Kinetics of the SARS-CoV-2 antibody response and serological estimation of time since infection.

Pelleau S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, Gardais S, Elgharbawy Y, Velay A, Gonzalez M, Nizou JY, Khelil N, Zannis K, Cockram C, Merkling SH, Meola A, Kerneis S, Terrier B, de Seze J, Planas D, Schwartz O, Dejardin F, Petres S, von Platen C, Pellerin SF, Arowas L, de Facci LP, Duffy D, Cheallaigh CN, Dunne J, Conlon N, Townsend L, Duong V, Auerswald H, Pinaud L, Tondeur L, Backovic M, Hoen B, Fontanet A, Mueller I, Fafi-Kremer S, Bruel T, White M

J Infect Dis. 2021 Jul 19;:

A rise in cases of nitrous oxide abuse: neurological complications and biological findings.

Einsiedler M, Voulleminot P, Demuth S, Kalaaji P, Bogdan T, Gauer L, Reschwein C, Nadaj-Pakleza A, de Sèze J, Kremer L, Schroder I, Bigaut K

J Neurol. 2021 Jul 10;:

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.

Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C, ,

Ann Clin Transl Neurol. 2021 Jul 7;:

Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection.

Bigaut K, Kremer L, Fleury M, Lanotte L, Collongues N, de Seze J

Rev Neurol (Paris). 2021 Jun 16;:

Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence.

Soares-Dos-Reis R, Tsz-Ching JL, Kim SH, Jacob A, Whittam D, Berthelot E, Paul F, Nakashima I, Tye JSN, De Seze J, Jitprapaikulsan J, Tan K, Yang L, Elsone L, Leite MI, Mealy MA, Levy M, Fan M, Siebert N, Asgari N, Cabre P, Siritho S, Pittock SJ, Wing-Ho SC, Senger T, Yeo T, Takai Y, Pandit L, Kim HJ, Palace J

Mult Scler Relat Disord. 2021 Jun 15;53:103080

How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).

Bigaut K, Cohen M, Durand-Dubief F, Maillard E, Planque E, Zephir H, Lebrun-Frenay C, de Seze J,

Mult Scler Relat Disord. 2021 Jun 10;53:103076

Leptomeningeal enhancement on post-contrast FLAIR images for early diagnosis of Susac syndrome.

Bellanger G, Biotti D, Adam G, Darcourt J, Roques M, Patsoura S, Savatovsky J, Obadia M, Menjot de Champfleur N, Charif M, Labauge P, Cotton F, Durand Dubief F, Tourdias T, Dulau C, Kremer S, De Sèze J, Ciron J, Varenne F, Viguier A, Lerebours F, Larrue V, Cognard C, Bonneville F

Mult Scler. 2021 May 14;:13524585211012349

Comparison of Simoa and Ella to assess serum neurofilament-light chain in multiple sclerosis.

Gauthier A, Viel S, Perret M, Brocard G, Casey R, Lombard C, Laurent-Chabalier S, Debouverie M, Edan G, Vukusic S, Lebrun-Frénay C, De Sèze J, Laplaud DA, Castelnovo G, Gout O, Ruet A, Moreau T, Casez O, Clavelou P, Berger E, Zephir H, Trouillet-Assant S, Thouvenot E,

Ann Clin Transl Neurol. 2021 Apr 8;:

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah MM, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Sèze J, Péré H, Veyer D, Sève A, Simon-Lorière E, Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, van der Werf S, Prazuck T, Schwartz O

Nat Med. 2021 Mar 26;:

Microglial Cell Morphology and Phagocytic Activity Are Critically Regulated by the Neurosteroid Allopregnanolone: A Possible Role in Neuroprotection.

Jolivel V, Brun S, Binamé F, Benyounes J, Taleb O, Bagnard D, De Sèze J, Patte-Mensah C, Mensah-Nyagan AG

Cells. 2021 Mar 21;10(3):

Time to walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS

Eur J Neurol. 2021 Mar 16;:

Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2.

Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, Wendling MJ, Meyer N, Planchais C, Rey D, Mouquet H, Reix N, Glady L, Hansmann Y, Bruel T, De Séze J, Fontanet A, Gonzalez M, Schwartz O, Fafi-Kremer S

J Infect Dis. 2021 Mar 7;:

Untreated patients with multiple sclerosis: a study of French expert centers.

Moisset X, Fouchard AA, Pereira B, Taithe F, Mathey G, Edan G, Ciron J, Brochet B, De Sèze J, Papeix C, Vermersch P, Labauge P, Defer G, Lebrun-Frenay C, Moreau T, Laplaud D, Berger E, Pelletier J, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Casez O, Cabre P, Montcuquet A, Créange A, Camdessanché JP, Bakchine S, Maurousset A, Hankiewicz K, Pottier C, Maubeuge N, Dimitri Boulos D, Nifle C, Vukusic S, Clavelou P,

Eur J Neurol. 2021 Mar 1;:

Pregnancy in Patients With AQP4-Ab, MOG-Ab or Double-Negative Neuromyelitis Optica Disorder.

Collongues N, Do Rego CA, Bourre B, Biotti MD, Marignier R, Silva AM, Santos E, Maillart E, Papeix C, Palace J, Leite MIS, De Seze J

Neurology. 2021 Feb 24;:

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.

Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, de Seze J, Repovic P, Chen H, Hanna J, Messer J, Miller C, Naismith RT

Ther Adv Neurol Disord. 2021 ;14:1756286421993999

Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study.

Rosado J, Pelleau S, Cockram C, Merkling SH, Nekkab N, Demeret C, Meola A, Kerneis S, Terrier B, Fafi-Kremer S, de Seze J, Bruel T, Dejardin F, Petres S, Longley R, Fontanet A, Backovic M, Mueller I, White MT

Lancet Microbe. 2020 Dec 21;:

Assessing the experience of the quality of care of patients living with multiple sclerosis and their caregivers: the MusiCare Questionnaire.

Veillard D, Baumstarck K, Edan G, Debouverie M, Wiertlewski S, De Sèze J, Clavelou P, Pelletier J, Verny C, Chauvin K, Elisabeth Cosson M, Loundou A, Auquier P

Eur J Neurol. 2020 Dec 16;:

Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003).

Collongues N, Kuhle J, Tsagkas C, Lamy J, Meyer N, Barro C, Parmar K, Amann M, Wuerfel J, Kappos L, Moreau T, de Seze J

Brain Behav. 2020 Dec 13;:e01998

First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients.

Ayrignac X, Bigaut K, Pelletier J, de Seze J, Demortiere S, Collongues N, Maarouf A, Pinna F, Aouinti S, Carra Dallière C, Kremer L, Charif M, Picot MC, Labauge P

Mult Scler Relat Disord. 2020 Dec 13;48:102686

Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.

Vukusic S, Ionescu I, Cornu C, Bossard N, Durand-Dubief F, Cotton F, Durelli L, Marignier R, Gignoux L, Laplaud DA, Moreau T, Clavelou P, De Seze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Trojano M, Patti F, Baulieu EE, Remontet L, El-Etr M

Mult Scler. 2020 Dec 3;:1352458520978218

Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors.

Solis M, Guffroy A, Lersy F, Soulier E, Gallais F, Renaud M, Douiri N, Argemi X, Hansmann Y, De Sèze J, Kremer S, Fafi-Kremer S

Viruses. 2020 Dec 2;12(12):

Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study.

de Sèze J, Devy R, Planque E, Delabrousse-Mayoux JP, Vandhuick O, Kabir M, Gherib A

Mult Scler Relat Disord. 2020 Nov 28;47:102659

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.

Alleg M, Solis M, Baloglu S, Cotton F, Kerschen P, Bourre B, Ahle G, Pruvo JP, Leclerc X, Vermersch P, Papeix C, Maillart É, Houillier C, Chabrot CM, Claise B, Malak S, Martin-Blondel G, Bonneville F, Caulier A, Marolleau JP, Bonnefoy JT, Agape P, Kennel C, Roussel X, Chauchet A, De Seze J, Fafi-Kremer S, Kremer S

Eur Radiol. 2020 Nov 6;:

Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO).

Specovius S, Zimmermann HG, Oertel FC, Chien C, Bereuter C, Cook LJ, Lana Peixoto MA, Fontenelle MA, Kim HJ, Hyun JW, Jung SK, Palace J, Roca-Fernandez A, Diaz AR, Leite MI, Sharma SM, Ashtari F, Kafieh R, Dehghani A, Pourazizi M, Pandit L, Dcunha A, Aktas O, Ringelstein M, Albrecht P, May E, Tongco C, Leocani L, Pisa M, Radaelli M, Martinez-Lapiscina EH, Stiebel-Kalish H, Hellmann M, Lotan I, Siritho S, de Seze J, Senger T, Havla J, Marignier R, Tilikete C, Cobo Calvo A, Bichuetti DB, Tavares IM, Asgari N, Soelberg K, Altintas A, Yildirim R, Tanriverdi U, Jacob A, Huda S, Rimler Z, Reid A, Mao-Draayer Y, de Castillo IS, Yeaman MR, Smith TJ, Brandt AU, Paul F,

BMJ Open. 2020 Oct 29;10(10):e035397

Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.

Louapre C, Maillart E, Papeix C, Zeidan S, Biotti D, Lepine Z, Wahab A, Zedet M, Labauge P, Tilikete C, Pique J, Tourbah A, Mathey G, Dimitri Boulos D, Branger P, Kremer LD, Marignier R, Collongues N, De Seze J

Eur J Neurol. 2020 Oct 26;:

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis.

Mathais S, Moisset X, Pereira B, Taithe F, Ciron J, Labauge P, Dulau C, Laplaud D, De Seze J, Pelletier J, Berger E, Lebrun-Frenay C, Castelnovo G, Edan G, Defer G, Vermersch P, Bourre B, Camdessanche JP, Magy L, Guennoc AM, Mathey G, Moreau T, Gout O, Heinzlef O, Maillart E, Vukusic S, Clavelou P,

Neurotherapeutics. 2020 Sep 22;:

Clinical features and risk of relapses in children and adults with MOGAD.

Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, Papeix C, Audoin B, Lépine AF, Maurey H, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Pierre M, Thouvenot E, Bourre B, Montcuquet A, Cohen M, Horellou P, Tintoré M, De Seze J, Vukusic S, Deiva K, Marignier R,

Ann. Neurol.. 2020 Sep 21;:

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.

Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T

Neurol Neuroimmunol Neuroinflamm. 2020 Sep 3;7(5):

Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Brochet B, Defer G, Vermersch P, Debouverie M, Berger E, Labauge P, De Sèze J, Brassat D, Lebrun C

Rev. Neurol. (Paris). 2020 Sep;176S:S76-S77

De Sèze J, Giovannoni G, Kappos L, Hauser SL, Köndgen H, Prajapati K, Wolinsky JS

Rev. Neurol. (Paris). 2020 Sep;176S:S83-S84

Guillain-Barré syndrome related to SARS-CoV-2 infection.

Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, Godon A, Voulleminot P, Kremer L, Chanson JB, de Seze J

Neurol Neuroimmunol Neuroinflamm. 2020 09;7(5):

Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies.

Velay A, Gallais F, Benotmane I, Wendling MJ, Danion F, Collange O, De Sèze J, Schmidt-Mutter C, Schneider F, Bilbault P, Meziani F, Fafi-Kremer S

Diagn. Microbiol. Infect. Dis.. 2020 Aug 21;98(4):115181

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L,

N. Engl. J. Med.. 2020 08 6;383(6):546-557

Identification and measurement of cervical spinal cord atrophy in neuromyelitis optica spectrum disorders (NMOSD) and correlation with clinical characteristics and cervical spinal cord MRI data.

Lersy F, Noblet V, Willaume T, Collongues N, Kremer L, Fleury M, de Seze J, Kremer S

Rev. Neurol. (Paris). 2020 Aug 1;:

Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.

Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, Staropoli I, Anna F, Souque P, Fernandes-Pellerin S, Jolly N, Renaudat C, Ungeheuer MN, Schmidt-Mutter C, Collongues N, Bolle A, Velay A, Lefebvre N, Mielcarek M, Meyer N, Rey D, Charneau P, Hoen B, De Seze J, Schwartz O, Fontanet A

EBioMedicine. 2020 Jul 31;:102915

COVID-19 in people with multiple sclerosis: A global data sharing initiative.

Peeters LM, Parciak T, Walton C, Geys L, Moreau Y, De Brouwer E, Raimondi D, Pirmani A, Kalincik T, Edan G, Simpson-Yap S, De Raedt L, Dauxais Y, Gautrais C, Rodrigues PR, McKenna L, Lazovski N, Hillert J, Forsberg L, Spelman T, McBurney R, Schmidt H, Bergmann A, Braune S, Stahmann A, Middleton R, Salter A, Bebo BF, Rojas JI, van der Walt A, Butzkueven H, van der Mei I, Ivanov R, Hellwig K, Sciascia do Olival G, Cohen JA, Van Hecke W, Dobson R, Magyari M, Brum DG, Alonso R, Nicholas R, Bauer J, Chertcoff A, de Sèze J, Louapre C, Comi G, Rijke N

Mult. Scler.. 2020 Jul 14;:1352458520941485

Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.

Bigaut K, Fabacher T, Kremer L, Ongagna JC, Kwiatkowski A, Sellal F, Ferriby D, Courtois S, Vermersch P, Collongues N, Zéphir H, De Seze J, Outteryck O

Mult. Scler.. 2020 Jul 9;:1352458520936239

Treatment of MOG antibody associated disorders: results of an international survey.

Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Pröbstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A

J. Neurol.. 2020 Jul 4;:

[Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder].

Osswald D, De Seze J, Collongues N, Speeg-Schatz C

J Fr Ophtalmol. 2020 Jul 3;:

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial.

Metzger-Peter K, Kremer LD, Edan G, Loureiro De Sousa P, Lamy J, Bagnard D, Mensah-Nyagan AG, Tricard T, Mathey G, Debouverie M, Berger E, Kerbrat A, Meyer N, De Seze J, Collongues N

Trials. 2020 Jun 29;21(1):591

Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, Deschamps R, Créange A, Wahab A, Pelletier J, Heinzlef O, Labauge P, Guilloton L, Ahle G, Goudot M, Bigaut K, Laplaud DA, Vukusic S, Lubetzki C, De Sèze J,

JAMA Neurol. 2020 Jun 26;:

Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.

Kerbrat A, Gros C, Badji A, Bannier E, Galassi F, Combès B, Chouteau R, Labauge P, Ayrignac X, Carra-Dalliere C, Maranzano J, Granberg T, Ouellette R, Stawiarz L, Hillert J, Talbott J, Tachibana Y, Hori M, Kamiya K, Chougar L, Lefeuvre J, Reich DS, Nair G, Valsasina P, Rocca MA, Filippi M, Chu R, Bakshi R, Callot V, Pelletier J, Audoin B, Maarouf A, Collongues N, De Seze J, Edan G, Cohen-Adad J

Brain. 2020 Jun 23;:

A comparative evaluation of different NeuroMyelitis Optica Spectrum Disorder sets criteria.

Papeix C, Beigneux Y, Maillart E, de Seze J, Lubetzki C, Vukusic S, Collongues N, Marignier R

Eur. J. Neurol.. 2020 Jun 19;:

Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study.

Kremer S, Lersy F, de Sèze J, Ferré JC, Maamar A, Carsin-Nicol B, Collange O, Bonneville F, Adam G, Martin-Blondel G, Rafiq M, Geeraerts T, Delamarre L, Grand S, Krainik A, Caillard S, Marc Constans J, Metanbou S, Heintz A, Helms J, Schenck M, Lefèbvre N, Boutet C, Fabre X, Forestier G, de Beaurepaire I, Bornet G, Lacalm A, Oesterlé H, Bolognini F, Messie J, Hmeydia G, Benzakoun J, Oppenheim C, Bapst B, Megdiche I, Henri-Feugeas MC, Khalil A, Gaudemer A, Jager L, Nesser P, Talla Mba Y, Hemmert C, Feuerstein P, Sebag N, Carré S, Alleg M, Lecocq C, Schmitt E, Anxionnat R, Zhu F, Comby PO, Ricolfi F, Thouant P, Desal H, Boulouis G, Berge J, Kazémi A, Pyatigorskaya N, Lecler A, Saleme S, Edjlali-Goujon M, Kerleroux B, Zorn PE, Mathieu M, Baloglu S, Ardellier FD, Willaume T, Brisset JC, Boulay C, Mutschler V, Hansmann Y, Mertes PM, Schneider F, Fafi-Kremer S, Ohana M, Meziani F, David JS, Meyer N, Anheim M, Cotton PF

Radiology. 2020 Jun 16;:202222

Memory improvement in multiple sclerosis after an extensive cognitive rehabilitation program in groups with a multicenter double-blind randomized trial.

Brissart H, Omorou AY, Forthoffer N, Berger E, Moreau T, De Seze J, Morele E, Debouverie M

Clin Rehabil. 2020 Jun;34(6):754-763

Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis.

Brochet B, Deloire M, Germain C, Ouallet JC, Wittkop L, Dulau C, Perez P, Thevenot F, De Sèze J, Zéphir H, Vermersch P, Pittion S, Debouverie M, Laplaud DA, Clavelou P, Ruet A

J Clin Apher. 2020 May 5;:

Covid-19, the pandemic war: Implication for neurologists.

de Seze J, Lebrun-Frenay C

Rev. Neurol. (Paris). 2020 May;176(4):223-224

Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.

Maillart E, Durand-Dubief F, Louapre C, Audoin B, Bourre B, Derache N, Ciron J, Collongues N, de Sèze J, Cohen M, Lebrun-Frenay C, Hadhoum N, Zéphir H, Deschamps R, Carra-Dallière C, Labauge P, Kerschen P, Montcuquet A, Wiertlewski S, Laplaud D, Runavot G, Vukusic S, Papeix C, Marignier R,

J Neuroinflammation. 2020 Apr 23;17(1):128

Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes.

de Seze J, Bigaut K

Rev. Neurol. (Paris). 2020 Apr 4;:

Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study.

Cobo-Calvo Á, d'Indy H, Ruiz A, Collongues N, Kremer L, Durand-Dubief F, Rollot F, Casey R, Vukusic S, De Seze J, Marignier R

Neurol Neuroimmunol Neuroinflamm. 2020 Mar;7(2):

Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.

Bigaut K, Lambert C, Kremer L, Lebrun C, Cohen M, Ciron J, Bourre B, Créange A, Kerschen P, Montcuquet A, Carra-Dalliere C, Ayrignac X, Labauge P, de Seze J, Collongues N

Mult. Scler.. 2020 Feb 20;:1352458520906995

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J

N. Engl. J. Med.. 2019 Nov 28;381(22):2114-2124

Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.

Bordet R, Camu W, De Seze J, Laplaud DA, Ouallet JC, Thouvenot E

Rev. Neurol. (Paris). 2019 Nov 19;:

Tumefactive inflammatory leukoencephalopathy in cocaine users: Report of three cases.

Pessini LM, Kremer S, Auger C, Castilló J, Pottecher J, de Sèze J, Lhermitte B, Maciag E, Rovira A

Mult Scler Relat Disord. 2019 Nov 4;38:101496

MSCopilot, a new Multiple Sclerosis self-assessment digital solution: results of a comparative study versus standard tests.

Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A

Eur. J. Neurol.. 2019 Sep 20;:

Expert opinion: Criteria for second-line treatment failure in patients with multiple sclerosis.

Vermersch P, De Sèze J, Clavelou P, Durand-Dubief F, Maillart E, Mekies C, Moreau T, Papeix C, Tourbah A, Labauge P

Mult Scler Relat Disord. 2019 Sep 19;36:101406

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA,

JAMA Neurol. 2019 Sep 3;:

Emotional disturbances in multiple sclerosis: A neuropsychological and fMRI study.

Pfaff L, Lamy J, Noblet V, Gounot D, Chanson JB, de Seze J, Blanc F

Cortex. 2019 08;117:205-216

Serum-based differentiation between multiple sclerosis and amyotrophic lateral sclerosis by Random Forest classification of FTIR spectra.

El Khoury Y, Collongues N, De Sèze J, Gulsari V, Patte-Mensah C, Marcou G, Varnek A, Mensah-Nyagan AG, Hellwig P

Analyst. 2019 Jul 1;:

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study.

Miller AE, Vermersch P, Kappos L, Comi G, Freedman MS, Oh J, de Seze J, Truffinet P, Benamor M, Purvis A, Wolinsky JS,

Mult Scler Relat Disord. 2019 May 24;33:131-138

Miller Fisher syndrome mimicking botulism: Clinical and pathophysiological discussion of a case.

Bigaut K, Kremer L, Hacquard A, Collongues N, De Seze J

Rev. Neurol. (Paris). 2019 Apr 29;:

Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.

Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, Kremer S

J. Neurol.. 2019 Apr 23;:

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S,

Mult. Scler.. 2019 Apr;25(4):591-600

A case of acute posterior multifocal placoid pigment epitheliopathy with aseptic meningitis and cerebral infarction.

Bigaut K, Kremer L, Hacquard A, Wolff B, Collongues N, De Seze J

Rev. Neurol. (Paris). 2019 Mar 27;:

FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis.

Kremer L, Taleb O, Boehm N, Mensah-Nyagan AG, Trifilieff E, de Seze J, Brun S

J Neuroinflammation. 2019 Mar 2;16(1):54

[Retrobulbar optic neuritis in a 15-year-old boy].

Taleb A, De Sèze J, Speeg-Schatz C, Sauer A

J Fr Ophtalmol. 2019 Feb 20;:

Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.

de Seze J

Curr. Opin. Neurol.. 2019 Feb;32(1):111-114

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options.

Collongues N, Ayme-Dietrich E, Monassier L, de Seze J

Drugs. 2019 Jan 8;:

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C

Mult Scler Relat Disord. 2019 Jan 6;29:7-14

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, 'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R, ,

J. Neurol.. 2019 Jan 3;:

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV

Front Neurol. 2019 ;10:253

Resting-state functional MRI demonstrates brain network reorganization in neuromyelitis optica spectrum disorder (NMOSD).

Bigaut K, Achard S, Hemmert C, Baloglu S, Kremer L, Collongues N, De Sèze J, Kremer S

PLoS ONE. 2019 ;14(1):e0211465

Ocrelizumab for the treatment of multiple sclerosis.

Bigaut K, de Seze J, Collongues N

Expert Rev Neurother. 2018 Dec 20;:

Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, Collongues N, Corti L, De Seze J, Lebrun C, Vukusic S, Durand-Dubief F, Labauge P,

Mult Scler Relat Disord. 2018 Dec 18;28:109-116

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M

Mult. Scler.. 2018 Dec 13;:1352458518815602

Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.

Ungureanu A, de Seze J, Ahle G, Sellal F

Rev. Neurol. (Paris). 2018 Dec;174(10):675-679

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B

Nervenarzt. 2018 Dec;89(12):1388-1399

Measurement of magnetization transfer ratio (MTR) from cervical spinal cord: Multicenter reproducibility and variability.

Combès B, Monteau L, Bannier E, Callot V, Labauge P, Ayrignac X, Carra Dallière C, Pelletier J, Maarouf A, de Seze J, Collongues N, Barillot C, Edan G, Ferré JC, Kerbrat A,

J Magn Reson Imaging. 2018 Oct 22;:

Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study.

Ernst A, Sourty M, Roquet D, Noblet V, Gounot D, Blanc F, de Seze J, Manning L

Neuropsychol Rehabil. 2018 Oct;28(7):1110-1130

Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Balloy G, Pelletier J, Suchet L, Lebrun C, Cohen M, Vermersch P, Zephir H, Duhin E, Gout O, Deschamps R, Le Page E, Edan G, Labauge P, Carra-Dallieres C, Rumbach L, Berger E, Lejeune P, Devos P, N'Kendjuo JB, Coustans M, Auffray-Calvier E, Daumas-Duport B, Michel L, Lefrere F, Laplaud DA, Brosset C, Derkinderen P, de Seze J, Wiertlewski S,

J. Neurol.. 2018 Oct;265(10):2251-2259

Late activity rebound in non-active multiple sclerosis: A rare event.

Corti L, Ayrignac X, Carra Dalliere C, Charif M, de Sèze J, Biotti D, Ciron J, Labauge P

Mult. Scler.. 2018 Oct;24(12):1649-1650

Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study.

Defer G, de Seze J, Bouee S, Courouve L, Longin J, Payet M, Deleglise ASJ,

Mult Scler Relat Disord. 2018 Oct;25:276-281

Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies.

Berzero G, Karantoni E, Dehais C, Ducray F, Thomas L, Picard G, Rogemond V, Candelier G, Camdessanché JP, Antoine JC, De Seze J, Liou-Schischmanoff A, Honnorat J, Delattre JY, Psimaras D

J. Neurol. Neurosurg. Psychiatry. 2018 Jul;89(7):789-792

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C

CNS Drugs. 2018 Jul;32(7):661-672

Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?

Fitsiori A, Fornecker LM, Simon L, Karentzos A, Galanaud D, Outteryck O, Vermersch P, Pruvo JP, Gerardin E, Lebrun-Frenay C, Lafitte F, Cottier JP, Clerc C, de Seze J, Dietemann JL, Kremer S

Eur Radiol. 2018 Jun 19;:

An autophagy-targeting peptide to treat chronic inflammatory demyelinating polyneuropathies.

Brun S, Schall N, Bonam SR, Bigaut K, Mensah-Nyagan AG, de Sèze J, Muller S

J. Autoimmun.. 2018 Jun 5;:

Demyelinating diseases.

Lebrun C, de Seze J

Rev. Neurol. (Paris). 2018 06;174(6):355

Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.

Combès B, Kerbrat A, Ferré JC, Callot V, Maranzano J, Badji A, Le Page E, Labauge P, Ayrignac X, Carra Dallière C, de Champfleur NM, Pelletier J, Maarouf A, de Seze J, Collongues N, Brassat D, Durand-Dubief F, Barillot C, Bannier E, Edan G,

Mult. Scler.. 2018 Jun 1;:1352458518781999

Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics.

Collongues N, Patte-Mensah C, De Seze J, Mensah-Nyagan AG, Derfuss T

Expert Rev Neurother. 2018 Jun;18(6):515-522

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R,

Neurology. 2018 May 22;90(21):e1858-e1869

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B

J Neuroinflammation. 2018 May 3;15(1):134

Ozone, NO and PM are associated with the occurrence of multiple sclerosis relapses. Evidence from seasonal multi-pollutant analyses.

Jeanjean M, Bind MA, Roux J, Ongagna JC, de Sèze J, Bard D, Leray E

Environ. Res.. 2018 May;163:43-52

The effect of oxysterols on nerve impulses.

Bezine M, Namsi A, Sghaier R, Ben Khalifa R, Hamdouni H, Brahmi F, Badreddine I, Mihoubi W, Nury T, Vejux A, Zarrouk A, de Sèze J, Moreau T, Nasser B, Lizard G

Biochimie. 2018 Apr 21;:

FDG PET and MRI Findings in a Case of Bing-Neel Syndrome.

Bund C, Lhermitte B, De Seze J, Kremer S, Namer IJ

Clin Nucl Med. 2018 Apr;43(4):262-264

Modulation of Kv3.1b potassium channel level and intracellular potassium concentration in 158N murine oligodendrocytes and BV-2 murine microglial cells treated with 7-ketocholesterol, 24S-hydroxycholesterol or tetracosanoic acid (C24:0).

Bezine M, Maatoug S, Ben Khalifa R, Debbabi M, Zarrouk A, Wang Y, Griffiths WJ, Nury T, Samadi M, Vejux A, de Sèze J, Moreau T, Kharrat R, El Ayeb M, Lizard G

Biochimie. 2018 Feb 17;:

High-intensity interval training combined with resistance training improves physiological capacities, strength and quality of life in multiple sclerosis patients: a pilot study.

Zaenker P, Favret F, Lonsdorfer E, Muff G, de Seze J, Isner-Horobeti ME

Eur J Phys Rehabil Med. 2018 Feb;54(1):58-67

Metabolomics approaches in experimental allergic encephalomyelitis.

Battini S, Bund C, Moussallieh FM, Çiçek AE, De Sèze J, Namer IJ

J. Neuroimmunol.. 2018 Jan 15;314:94-100

Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy.

Collongues N, Samama B, Schmidt-Mutter C, Chamard-Witkowski L, Debouverie M, Chanson JB, Antal MC, Benardais K, de Seze J, Velten M, Boehm N

PLoS ONE. 2018 ;13(1):e0191614

MOG-antibody neuromyelitis optica spectrum disorder: is it a separate disease?

de Seze J

Brain. 2017 Dec 1;140(12):3072-3075

Multiple sclerosis treatments and the anti-JCV antibody index.

de Seze J, Lebrun-Frenay C

Rev. Neurol. (Paris). 2017 12;173(10):e1

The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis.

Leva G, Klein C, Benyounes J, Hallé F, Bihel F, Collongues N, De Seze J, Mensah-Nyagan AG, Patte-Mensah C

Biochim Biophys Acta Mol Basis Dis. 2017 12;1863(12):3016-3027

Radiologically isolated syndrome in children: Clinical and radiologic outcomes.

Makhani N, Lebrun C, Siva A, Brassat D, Carra Dallière C, de Seze J, Du W, Durand Dubief F, Kantarci O, Langille M, Narula S, Pelletier J, Rojas JI, Shapiro ED, Stone RT, Tintoré M, Uygunoglu U, Vermersch P, Wassmer E, Okuda DT, Pelletier D

Neurol Neuroimmunol Neuroinflamm. 2017 Nov;4(6):e395

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A, ,Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S

Mult Scler Relat Disord. 2017 11;18:161-163

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC

Neurology. 2017 Oct 10;89(15):1584-1593

Assessing Autophagy in Sciatic Nerves of a Rat Model that Develops Inflammatory Autoimmune Peripheral Neuropathies.

Brun S, Schall N, Jeltsch-David H, Sèze J, Muller S

Cells. 2017 Sep;6(3):

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R,

Mult. Scler.. 2017 Sep;23(10):1377-1384

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M,

Ann. Neurol.. 2017 Aug;82(2):186-195

Air pollution by particulate matter PM may trigger multiple sclerosis relapses.

Roux J, Bard D, Le Pabic E, Segala C, Reis J, Ongagna JC, de Sèze J, Leray E

Environ. Res.. 2017 07;156:404-410

Autophagy in neuroinflammatory diseases.

Muller S, Brun S, René F, de Sèze J, Loeffler JP, Jeltsch-David H

Autoimmun Rev. 2017 May;:

Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.

Collongues N, Michel L, de Seze J

Curr Treat Options Neurol. 2017 May;19(5):19

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C

Neurol Neuroimmunol Neuroinflamm. 2017 May;4(3):e346

Evidence of K(+) homeostasis disruption in cellular dysfunction triggered by 7-ketocholesterol, 24S-hydroxycholesterol, and tetracosanoic acid (C24:0) in 158N murine oligodendrocytes.

Bezine M, Debbabi M, Nury T, Ben-Khalifa R, Samadi M, Cherkaoui-Malki M, Vejux A, Raas Q, de Sèze J, Moreau T, El-Ayeb M, Lizard G

Chem. Phys. Lipids. 2017 Mar;:

Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.

Juryńczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, Waters P, Kuker W, Craner M, Weir A, DeLuca GC, Kremer S, Leite MI, Vincent A, Jacob A, de Sèze J, Palace J

J. Neurol. Neurosurg. Psychiatry. 2017 Feb;88(2):132-136

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS,

N. Engl. J. Med.. 2017 01 19;376(3):209-220

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A,

PLoS ONE. 2017 ;12(1):e0168834

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D,

Neurology. 2016 12 6;87(23):2491-2494

Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets.

de Sèze J, Kremer L, Alves do Rego C, Taleb O, Lam D, Beiano W, Mensah-Nyagan G, Trifilieff E, Brun S

Rev. Neurol. (Paris). 2016 Dec;172(12):767-769

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J,

Mult. Scler.. 2016 11;22(13):1719-1731

Giving meaning to illness: An investigation of self-defining memories in patients with relapsing-remitting multiple sclerosis patients.

Voltzenlogel V, Ernst A, de Sèze J, Brassat D, Manning L, Berna F

Conscious Cogn. 2016 10;45:200-209

False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.

Cohen M, De Sèze J, Marignier R, Lebrun C

Mult. Scler.. 2016 08;22(9):1231-4

Efficacy of rituximab in refractory neuromyelitis optica.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R,

Mult. Scler.. 2016 06;22(7):955-9

Functional and structural cerebral changes in key brain regions after a facilitation programme for episodic future thought in relapsing-remitting multiple sclerosis patients.

Ernst A, Sourty M, Roquet D, Noblet V, Gounot D, Blanc F, De Seze J, Manning L

Brain Cogn. 2016 06;105:34-45

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.

Collongues N, de Seze J

Ther Adv Neurol Disord. 2016 May;9(3):180-8

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G

J. Neurol. Sci.. 2016 Apr 15;363:69-76

Distinct and common cerebral activation changes during mental time travel in relapsing-remitting multiple sclerosis patients.

Ernst A, Noblet V, Denkova E, Blanc F, De Seze J, Gounot D, Manning L

Brain Imaging Behav. 2016 Mar;10(1):296-313

Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study.

Berna F, Blanc F, Lebrun C, Castelnovo G, Clerc C, Debouverie M, Jouvenoz D, Marcel-Viallet M, Zaenker C, Zephir H, Vidailhet P, De Sèze J

Mult Scler Relat Disord. 2016 Mar;6:93-6

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J

J. Neurol.. 2016 Jan;263(1):140-9

Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.

Chan A, de Seze J, Comabella M

CNS Drugs. 2016 Jan;30(1):41-51

[Difficulties experienced at work by patients with multiple sclerosis].

Ongagna JC, Passadori A, Pinelli J, Isner-Horobeti ME, Zaenker C, De Seze J

Rev. Neurol. (Paris). 2015 Nov;171(11):782-6

Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE.

Guffroy A, Dima A, Nespola B, Poindron V, Sibilia J, Herbrecht R, De Seze J, Habersetzer F, Andres E, Quoix E, Ohlmann P, Cribier B, Langer B, Martin T, Pasquali JL, Goetz J, Korganow AS

Joint Bone Spine. 2015 Sep 30. pii: S1297-319X(15)00151-7

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima,O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S

Neurol Neuroimmunol Neuroinflamm. 2015 Aug;2(4):e134

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG,

Neurology. 2015 Jul 14;85(2):177-89

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT, ,Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K

JAMA Neurol. 2015 Jul;72(7):815-22

Dalfampridine in hereditary spastic paraplegia: a prospective, open study.

Béreau M, Anheim M, Chanson JB, Tio G, Echaniz-Laguna A, Depienne C, Collongues N, de Sèze J

J. Neurol.. 2015 May;262(5):1285-8

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P

J Neurol. 2015 May 1.

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul F,

Mult. Scler.. 2015 May;21(6):678-88

Targeted clinical audits immediately following the establishment of clinical practice guidelines for multiple sclerosis in 17 neurology departments: A pragmatic and collaborative study.

Lairy G, Zephir H, Ouallet JC, Le Page E, Laplaud D, Bensa C, De Seze J

Rev. Neurol. (Paris). 2015 May;171(5):407-14

[Unilateral mydriasis in Lyme neuroborreliosis].

Felten R, Benoilid A, Alves Do Rego C, Collongues N, De Seze J

Rev. Neurol. (Paris). 2015 May;171(5):451-2

Challenges and opportunities in designing clinical trials for neuromyelitis optica.

Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR,

Neurology. 2015 Apr 28;84(17):1805-15

Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome.

Lebrun C, Forzy G, Collongues N, Cohen M, de Seze J, Hautecoeur P,

Rev. Neurol. (Paris). 2015 Apr;171(4):390-3

MRI characteristics of neuromyelitis optica spectrum disorder: an international update.

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH,

Neurology. 2015 Mar 17;84(11):1165-73

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T

J Neuroinflammation. 2015 Mar 8;12:46

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P

Brain. 2015 Feb;138(Pt 2):284-92

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D

J. Neurol.. 2015 Feb;262(2):326-36

Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies.

Brun S, Beaino W, Kremer L, Taleb O, Mensah-Nyagan AG, Lam CD, Greer JM, de Seze J, Trifilieff E

J. Neuroimmunol.. 2015 Jan 15;278:1-10

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G

PLoS ONE. 2015 ;10(7):e0132033

Functional cerebral changes in multiple sclerosis patients during an autobiographical memory test.

Ernst A, Noblet V, Denkova E, Blanc F, de Seze J, Gounot D, Manning L

Memory. 2015 ;23(8):1123-39

Neural correlates of episodic future thinking impairment in multiple sclerosis patients.

Ernst A, Noblet V, Gounot D, Blanc F, de Seze J, Manning L

J Clin Exp Neuropsychol. 2015 ;37(10):1107-23

Using mental visual imagery to improve autobiographical memory and episodic future thinking in relapsing-remitting multiple sclerosis patients: A randomised-controlled trial study.

Ernst A, Blanc F, De Seze J, Manning L

Restor. Neurol. Neurosci.. 2015 ;33(5):621-38

[Two new oral disease modifying therapies in relapsing remitting multiple sclerosis].

Lebrun C, de Seze J

Rev. Neurol. (Paris). 2014 Dec;170(12):721-2

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Manceau P, Latarche C, Pittion S, Edan G, de Sèze J, Massart C, Debouverie M

BMC Neurol. 2014 Nov 30;14:215

Significant and Meaningful Improvement in Treatment Satisfaction with Teriflunomide Versus Subcutaneous IFNB-1A in Patients with Relapsing MS Results from Tenere.

Mäurer M, Van Wijmeersch B, de Seze J, Meca-Lallana J, Bozzi S, Vermersch P

Value Health. 2014 Nov;17(7):A403

Impaired mental simulation of specific past and future personal events in non-depressed multiple sclerosis patients.

Ernst A, Blanc F, de Seze J, Sellal F, Chauvin B, Manning L

J. Neurol. Sci.. 2014 Oct 15;345(1-2):68-74

Extensive cerebral white matter involvement in a patient with NMO spectrum disorder.

Ayrignac X, Dalière CC, Nerrant E, Vincent T, De Seze J, Labauge P

Mult. Scler.. 2014 Sep;20(10):1401-3

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.

Collongues N, Marignier R, Jacob A, Leite MI, Siva A, Paul F, Zephir H, Akman-Demir G, Elsone L, Jarius S, Papeix C, Mutch K, Saip S, Wildemann B, Kitley J, Karabudak R, Aktas O, Kuscu D, Altintas A, Palace J, Confavreux C, De Seze J

Mult. Scler.. 2014 07;20(8):1086-94

Serum analysis by 1H nuclear magnetic resonance spectroscopy: a new tool for distinguishing neuromyelitis optica from multiple sclerosis.

Moussallieh FM, Elbayed K, Chanson JB, Rudolf G, Piotto M, De Seze J, Namer IJ

Mult Scler. 2014 Apr;20(5):558-65

Lyme neuroborreliosis and dementia.

Blanc F, Philippi N, Cretin B, Kleitz C, Berly L, Jung B, Kremer S, Namer IJ, Sellal F, Jaulhac B, de Seze J

J. Alzheimers Dis.. 2014 ;41(4):1087-93

Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study.

Chanson JB, Echaniz-Laguna A, Blanc F, Lacour A, Ballonzoli L, Kremer S, Namer IJ, Lannes B, Tranchant C, Vermersch P, de Seze J

J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):392-7

Longitudinal change detection: inference on the diffusion tensor along white matter pathways.

Grigis A, Noblet V, Blanc F, Heitz F, de Seze J, Kremer S, Armspach JP

Med Image Anal. 2013 Apr;17(3):375-86

Cognitive Dysfunction and Dementia in Primary Sjogren's Syndrome.

Blanc F, Longato N, Jung B, Kleitz C, Di Bitonto L, Cretin B, Collongues N, Sordet C, Fleury M, Poindron V, Gottenberg JE, Anne O, Lipsker D, Martin T, Sibilia J, de Seze J

ISRN Neurol. 2013 Sep 19;2013:501327

Longitudinal change detection in diffusion MRI using multivariate statistical testing on tensors.

Grigis A, Noblet V, Heitz F, Blanc F, de Sèze J, Kremer S, Rumbach L, Armspach JP

Neuroimage. 2012 May 1;60(4):2206-21

PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis.

Chanson JB, Diaconu M, Honnorat J, Martin T, De Seze J, Namer IJ, Hirsch E

Epileptic Disord. 2012 Mar;14(1):90-3

White matter atrophy and cognitive dysfunctions in neuromyelitis optica.

Blanc F, Noblet V, Jung B, Rousseau F, Renard F, Bourre B, Longato N, Cremel N, Di Bitonto L, Kleitz C, Collongues N, Foucher J, Kremer S, Armspach JP, de Seze J

PLoS ONE. 2012 ;7(4):e33878

Longitudinal change detection: inference on the diffusion tensor along white-matter pathways.

Grigis A, Noblet V, Blanc F, Heitz F, de Seze J, Armspach JP

Med Image Comput Comput Assist Interv. 2011 ;14(Pt 2):1-8

Magnetic resonance spectroscopy evaluation in patients with neuromyelitis optica.

de Seze J, Blanc F, Kremer S, Collongues N, Fleury M, Marcel C, Namer IJ

J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):409-11.

Acute limbic encephalitis and glutamic acid decarboxylase antibodies: a reality?

Blanc F, Ruppert E, Kleitz C, Valenti MP, Cretin B, Humbel RL, Honnorat J, Namer IJ, Hirsch E, Manning L, de Seze J

J Neurol Sci. 2009 Dec 15;287(1-2):69-71

Foreign accent syndrome as a first sign of multiple sclerosis.

Chanson JB, Kremer S, Blanc F, Marescaux C, Namer IJ, de Seze J

Mult Scler. 2009 Sep;15(9):1123-5

Interest of the non conventional IRM in optical neuromyelitis of Devic

de Seze J, Collongues N, Blanc F, Fleury M, Rousseau F, Marcel C, Armspach JP, Dietemann JL, Namer I, Kremer S

Rev Neurol. 2009 Jan;165 Suppl. 1:S2-3